Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biomarker for NMOSD prediction or recurrence monitoring and application thereof

A biomarker and protein technology, applied in the field of biomarkers, can solve problems such as inability to meet clinical needs, and achieve the effect of improving clinical services

Active Publication Date: 2021-09-07
BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
View PDF9 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no recognized biomarker with high predictive value for the onset and disease progression of NMOSD so far, which cannot meet the clinical needs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarker for NMOSD prediction or recurrence monitoring and application thereof
  • Biomarker for NMOSD prediction or recurrence monitoring and application thereof
  • Biomarker for NMOSD prediction or recurrence monitoring and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Embodiment 1: The clinical data collection of NMOSD patient and healthy control group

[0056] This study included inpatients in Beijing Tiantan Hospital Affiliated to Capital Medical University from October 2018 to November 2019. Inclusion criteria for NMOSD patients: (1) The age of onset is between 18 and 80; (2) NMOSD patients are clearly diagnosed according to the 2015 Wingerchuk NMOSD diagnostic criteria; (3) Blood AQP4 antibody positive; (4) This is an acute attack : (a) Neurological symptoms such as optic neuritis, transverse myelitis, or acute brain injury that appear newly or are significantly worse than before (i.e. patients must seek medical attention within 7 days after the onset of symptoms). (b) New-onset symptoms must persist for at least 48 hours and not be attributable to other clinical factors (eg, fever, infection, injury, adverse reaction to concomitant medication). (c) New onset symptoms must be consistent with objective clinical signs of sensory, ...

Embodiment 2

[0057] Example 2: Sample collection and storage of NMOSD patients and healthy controls

[0058] 1. Collection of plasma: Collect peripheral blood in purple tubes containing anticoagulant EDTA or heparin, and centrifuge within 30 minutes after sample collection, at 3000 rpm for 10 minutes, at 2-8°C. The upper plasma layer was collected and stored in batches at -80°C. Avoid repeated freezing and thawing of samples. Note: Samples should be centrifuged sufficiently to avoid hemolysis or the presence of particles.

[0059] 2. Extraction of exosomes in peripheral plasma

[0060] Astrocyte-derived exosomes in plasma were extracted by immunosorbent assay.

[0061] 2.1 Magnetic beads (Beads) coated antibody

[0062] 1) Add 100ug of astrocyte surface glutamate transporter antibody (EAAT2-IgG) into the ultrafiltration tube and wash repeatedly;

[0063] 2) Add 8-10ul of biotin (Biotin) with a final concentration of 10mM to the IgG, and let it stand at room temperature for 1-2 hours; ...

Embodiment 3

[0084] Example 3: Proteomics technology analysis, screening out differentially expressed proteins, and obtaining a detection combination of prognostic biomarkers

[0085] 1. The present invention uses the next-generation non-labeled quantitative proteomics technology to complete the analysis. In the data independent acquisition (DIA) mode, it can provide unparalleled proteome coverage and realize the detection of a large number of proteins in each sample at the same time. Precise, highly reproducible quantification. The DIA process provides an ideal platform for qualitative analysis of differentially expressed proteomes or quantitative proteomes of massive samples. The DIA process is based on three necessary steps:

[0086] 1) Construct a spectral library: The spectral library collects all detectable non-redundant high-quality peptide information (MS / MS spectra) of the sample, and serves as a peptide identification template for subsequent data analysis. It contains fragment ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a biomarker for NMOSD prediction or recurrence monitoring and application of the biomarker. By preparing a reagent or a kit capable of detecting and analyzing the expression level of the biomarker, the corresponding biomarker in peripheral blood or plasma exosome of a subject is detected, so that the neuromyelitis optica pedigree disease can be predicted and monitored; not only can the onset risk of the neuromyelitis optica pedigree disease of the subject be predicted, but also the recurrence of the neuromyelitis optica pedigree disease of the patient or the subject can be monitored. The present invention provides the biomarker for NMOSD prediction or recurrence monitoring, which is helpful to better understand the pathophysiology of NMOSD, thereby improving clinical service for NMOSD patients.

Description

technical field [0001] The present invention relates to biomarker technology, in particular to biomarkers that can be used for NMOSD analysis. Background technique [0002] Neuromyelitis optica spectrum disease (NMOSD) is an immune demyelinating disease of the central nervous system, mainly acute or subacute demyelinating lesions involving simultaneous or sequential involvement of the optic nerve and spinal cord. For a long time, there has been controversy over whether NMOSD is an independent disease or a variant of multiple sclerosis (MS). Since Lennon et al. (2004) discovered aquaporin-4 (AQP4) antibodies in the serum of neuromyelitis optica (NMO) patients, NMOSD, as an independent disease different from MS, is a humoral immunity-based disease. The main autoimmune diseases of the central nervous system have been generally recognized. The mechanism is that the specific antibody produced by sensitized B lymphocytes binds to complement, deposits and destroys AQP4 on the sur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
CPCG01N33/6893G01N2800/285
Inventor 施福东金薇娜李昕頔田德财魏常娟
Owner BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com